Nine Diagnostics and Orbits Oncology have executed a Letter of Intent (LOI) to jointly develop a next-generation precision oncology diagnostics platform. This collaboration brings together two complementary, cutting-edge systems: Nine’s nanosensor-based molecular fingerprinting platform—which captures integrated disease signals directly from blood—and Orbit Oncology’s organoid-based functional drug-response platform, which measures how a patient’s tumor responds to therapies ex vivo. Together, they enable a closed-loop view of disease state and therapeutic efficacy. The partnership will focus initially on feasibility, including integrated workflow development, early multimodal dataset generation, and validation planning in oncology indications such as lung cancer and renal cell carcinoma. The objective is to generate the first combined datasets linking systemic molecular fingerprints with functional tumor response—creating a new category of precision diagnostics. This work builds directly on the platform Nine Diagnostics is commercializing and extends its capabilities into functional validation. It also reflects the broader ecosystem emerging around these technologies, including connections through the Merck Digital Sciences Studio, reinforcing the growing convergence of advanced sensing, AI-driven analytics, and functional oncology systems. The goal is to establish clear scientific and translational proof points that support downstream clinical development and commercialization pathways in precision oncology.
